NEW YORK, Sept. 19 - Illumina and GlaxoSmithKline will turn a "large" set of SNP markers into SNP assays that Illumina will use to create a whole-genome linkage disequilibrium-mapping product to be deployed with its BeadArray platform, the companies said today.
Meantime, Glaxo will use the platform to genotype patient samples and disease populations, and will evaluate the use of high-density SNP-evaluation studies in the search for disease loci, according to Illumina.
The partners will co-create "performance criteria," evaluate candidate SNP markers, and select an "extensive" set for assay development. Illumina said the assay development will take place "over several month."
Click here for more information.